Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout

Altoona Center for Clinical Research, Duncansville

Mid Atlantic Research Assoc., Philadelphia

Veterans Affairs Medical Center, Washington D.C.

Center for Rheumatology and Bone Research, Wheaton

Peter A. Holt, M.D., Baltimore

Duke University Medical Center, Durham

Arthritis & Rheumatic Disease Specialties, Aventura

St. Petersburg Arthritis Center, St. Petersburg

Ocala Rheumatology Research Center, Ocala

Graves Gilbert Clinic, Bowling Green

The Ohio State University, Columbus

David R. Mandel, MD, Inc., Mayfield Village

New Horizons Clinical Research, Cincinnati

STAT Research, Inc., Dayton

Justus J. Fiechtner, MD, PC, Lansing

CentraCare Clinic, Saint Cloud

The University of Chicago, Chicago

Agilence Arthritis & Osteoporosis Medical Center, Whittier

Pacific Arthritis Center Medical Group, Santa Maria

Kaiser Permanente Medical Center, Clinical Trials Unit, San Francisco

Arthritis Northwest, PLLC, Spokane

Rheumatology Associates of North Jersey, Teaneck